By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biofrontera AG 

Hemmelrather Weg 201

Leverkusen    51377  Germany
Phone: 49-0-214-87632-0 Fax: 49-0-214-87632-90


SEARCH JOBS


Industry
Pharmaceutical






Company News
Biofrontera AG Initiates Phase III Trial Of Ameluz In Combination With Daylight-PDT 6/30/2016 12:22:28 PM
Biofrontera AG Announces NDA Progress Update For BF-200 ALA 4/5/2016 1:23:23 PM
Biofrontera AG Release: Swiss Compulsory Health Insurance Reimburses Ameluz For Treatment Of Actinic Keratosis 4/1/2016 12:19:18 PM
Biofrontera AG Announces Full Results Of Phase III Clinical Trial Evaluating BF-200 ALA For Treatment Of Basal Cell Carcinoma (BCC) 3/7/2016 12:48:03 PM
Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy And Excellent Safety For BF-200 ALA Treatment Of Superficial Skin Cancer 2/11/2016 10:39:07 AM
DNAPrint Genomics Inc. (DNAP) Partner, Biofrontera AG, Commences Trading On Frankfurt Stock Exchange 11/1/2006 10:37:40 AM
DNAPrint Genomics Inc. (DNAP) Partner, Biofrontera AG., Commences Trading On German Stock Exchanges 10/31/2006 10:29:04 AM
DNAPrint Genomics Inc. (DNAP) Congratulates Biofrontera AG On Successful Clinical Trial Stages For Two Drugs 10/5/2006 10:29:34 AM
Discovery Partners International (DPII) Announce Signing Of Binding Letter Of Intent To Acquire Biofrontera Discovery GmbH10/19/2005 5:12:52 PM
//-->